Advertisement
Australia markets closed

  • ALL ORDS

    7,817.40
    -81.50 (-1.03%)
     

  • ASX 200

    7,567.30
    -74.80 (-0.98%)
     

  • AUD/USD

    0.6423
    -0.0002 (-0.04%)
     

  • OIL

    83.52
    +0.79 (+0.95%)
     

  • GOLD

    2,408.80
    +10.80 (+0.45%)
     

  • Bitcoin AUD

    100,746.89
    +2,872.40 (+2.93%)
     

  • CMC Crypto 200

    1,382.77
    +70.15 (+5.35%)
     

  • AUD/EUR

    0.6026
    -0.0005 (-0.08%)
     

  • AUD/NZD

    1.0900
    +0.0025 (+0.23%)
     

  • NZX 50

    11,796.21
    -39.83 (-0.34%)
     

  • NASDAQ

    17,150.84
    -243.48 (-1.40%)
     

  • FTSE

    7,895.85
    +18.80 (+0.24%)
     

  • Dow Jones

    38,044.93
    +269.55 (+0.71%)
     

  • DAX

    17,737.36
    -100.04 (-0.56%)
     

  • Hang Seng

    16,224.14
    -161.73 (-0.99%)
     

  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

BiomX to Present at Upcoming September Investor Conferences

BiomX
·1-min read

BRANFORD, Conn. and NESS ZIONA, Israel, Sept. 02, 2021 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced Jonathan Solomon, Chief Executive Officer, will be presenting at three upcoming virtual investor events in September.

Presentation Details:

Event: H.C. Wainwright 23rd Annual Global Investments Conference
Date: Monday, Sept. 13, 2021
Time: 7:00 a.m. EDT

Event: Oppenheimer Virtual Fall Healthcare Life Science & MedTech Summit
Date: Monday, Sept. 20, 2021
Time: 1:15 – 1:55 p.m. EDT

ADVERTISEMENT

Event: Cantor 2021 Virtual Global Healthcare Conference
Date: Thursday, Sept. 30, 2021
Time: 11:20 a.m. EDT

Live webcasts of the three presentations will be accessible through the Investors section of the Company’s website at https://ir.biomx.com/news-events/ir-calendar. Following the events, the webcasts will be archived on the BiomX website.

About BiomX

BiomX is a clinical-stage microbiome company developing both natural and engineered phage cocktails designed to target and destroy bacteria that affect the appearance of skin, as well as target bacteria in the treatment of chronic diseases, such as inflammatory bowel disease, primary sclerosing cholangitis, cystic fibrosis, atopic dermatitis and colorectal cancer. BiomX discovers and validates proprietary bacterial targets and customizes phage compositions against these targets.

Additional information is available at www.biomx.com, the content of which does not form a part of this press release.

BiomX, Inc.
Assaf Oron
Chief Business Officer
+972 (54) 222-8901
assafo@biomx.com

Investors:
John Mullaly
LifeSci Advisors, LLC
(617) 429-3548
jmullaly@lifesciadvisors.com

Source: BiomX Inc